Timofeeva A A
Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(11):145-51.
Late stages of Parkinson's disease (PD) are characterized by the development of motor fluctuations and dyskinesia which inevitably emerge during the disease due to long-term use of levodopa and hinder treatment. The use of intestinal levodopa/carbidopa gel stabilizes the drug blood concentration and reduces the severity of motor parkinsonian symptoms. The literature of the last two decades on the efficacy and safety of intrarenal introduction of intestinal levodopa/carbidopa gel in PD patients is reviewed.A data analysis of intestinal levodopa/carbidopa gel revealed the efficacy of this method in the late stages of PD. The drug reduced motor symptoms, severity of motor fluctuations and dyskinesia and improved quality of life. Some studies demonstrated the decrease in PD stage, as evaluated by Hoehn and Yahr, during treatment with intestinal levodopa/carbidopa gel. The good tolerability profile allows for possibility of using this method for multiyear treatment. Side-effects were mostly related to drug delivery. All of them may be overcome in future in the process of technical improvement.
帕金森病(PD)晚期的特征是出现运动波动和异动症,由于长期使用左旋多巴,这些症状在疾病过程中不可避免地会出现,并阻碍治疗。使用肠内左旋多巴/卡比多巴凝胶可稳定药物血药浓度并减轻帕金森运动症状的严重程度。本文综述了过去二十年关于向帕金森病患者肾内输注肠内左旋多巴/卡比多巴凝胶的疗效和安全性的文献。对肠内左旋多巴/卡比多巴凝胶的数据分析揭示了该方法在帕金森病晚期的疗效。该药物减轻了运动症状、运动波动和异动症的严重程度,并改善了生活质量。一些研究表明,在用肠内左旋多巴/卡比多巴凝胶治疗期间,根据霍恩和雅尔分级评估,帕金森病阶段有所降低。良好的耐受性使得该方法有可能用于多年治疗。副作用大多与药物给药有关。所有这些副作用在未来技术改进过程中都可能被克服。